Rory Mullen outlines Ireland’s importance to multinational pharma in the changing EU landscape.
Despite recent changes in corporate tax law, Ireland remains an attractive partner in the development and manufacture of biopharmaceuticals, writes Rory Mullen of IDA Ireland.